Literature DB >> 7678397

Targeted radionuclide therapy for bone metastases.

V J Lewington1.   

Abstract

Recent advances in targeted radiotherapy offer a new approach for the management of metastatic bone pain. This paper will review the scientific basis for radionuclide therapy and will examine the evidence for clinical efficacy. The therapeutic potential of targeted radiotherapy can only be appreciated by comparison with established treatments. Alternative treatment options will, therefore, be discussed, to bring the potential advantages and hazards of targeted radiotherapy into perspective and to define its place in routine management.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7678397     DOI： 10.1007/bf02261248

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


  38 in total

1.  A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

Authors:  J H Turner; P G Claringbold
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

2.  Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.

Authors:  G M Blake; M A Zivanovic; R M Blaquiere; D R Fine; A J McEwan; D M Ackery
Journal:  J Nucl Med       Date:  1988-04       Impact factor: 10.057

3.  Results of 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report.

Authors:  N Firusian; P Mellin; C G Schmidt
Journal:  J Urol       Date:  1976-12       Impact factor: 7.450

4.  Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.

Authors:  A H Laing; D M Ackery; R J Bayly; R B Buchanan; V J Lewington; A J McEwan; P M Macleod; M A Zivanovic
Journal:  Br J Radiol       Date:  1991-09       Impact factor: 3.039

5.  Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

Authors:  H R Maxon; L E Schroder; V S Hertzberg; S R Thomas; E E Englaro; R Samaratunga; H Smith; J S Moulton; C C Williams; G J Ehrhardt
Journal:  J Nucl Med       Date:  1991-10       Impact factor: 10.057

6.  Phosphorus-32 for intractable bony pain from carcinoma of the prostate.

Authors:  N G Burnet; G Williams; N Howard
Journal:  Clin Oncol (R Coll Radiol)       Date:  1990-07       Impact factor: 4.126

7.  89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma.

Authors:  G M Blake; M A Zivanovic; A J McEwan; V B Batty; D M Ackery
Journal:  Eur J Nucl Med       Date:  1987

8.  Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases.

Authors:  P Price; P J Hoskin; D Easton; D Austin; S G Palmer; J R Yarnold
Journal:  Radiother Oncol       Date:  1986-08       Impact factor: 6.280

9.  Pain in far-advanced cancer.

Authors:  Robert G Twycross; Sarah Fairfield
Journal:  Pain       Date:  1982-11       Impact factor: 6.961

10.  Iodine-131-labeled diphosphonates for the palliative treatment of bone metastases: I. Organ distribution and kinetics of I-131 BDP3 in rats.

Authors:  M Eisenhut
Journal:  J Nucl Med       Date:  1984-12       Impact factor: 10.057
View more
  17 in total

1.  Future directions for unsealed source radionuclide therapy for bone metastases.

Authors:  V R McCready; J M O'Sullivan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-16       Impact factor: 9.236

Review 2.  Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons.

Authors:  Tapas Das; Sharmila Banerjee
Journal:  Clin Exp Metastasis       Date:  2016-12-17       Impact factor: 5.150

3.  May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.

Authors:  Amir Sabet; Feras Khalaf; Soha Mahjoob; Abdullah Al-Zreiqat; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

4.  Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Authors:  W Y Lin; C P Lin; S J Yeh; B T Hsieh; Z T Tsai; G Ting; T C Yen; S J Wang; F F Knapp; M G Stabin
Journal:  Eur J Nucl Med       Date:  1997-06

5.  The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Authors:  Knut Liepe; Roswitha Runge; Jörg Kotzerke
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-22       Impact factor: 4.553

Review 6.  186Re-HEDP for metastatic bone pain in breast cancer patients.

Authors:  Marnix G E H Lam; John M H de Klerk; Peter P van Rijk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-29       Impact factor: 9.236

Review 7.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Genotoxic and cytotoxic effects of 60Co gamma-rays and 90Sr/90Y beta-rays on Chinese hamster ovary cells (CHO-K1).

Authors:  Daniella Murakami; Miriam Fussae Suzuki; Mauro da Silva Dias; Kayo Okazaki
Journal:  Radiat Environ Biophys       Date:  2004-05-11       Impact factor: 1.925

9.  Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases.

Authors:  J Liu; J Li; Y Fan; K Chang; X Yang; W Zhu; X Wu; Yan Pang
Journal:  Ir J Med Sci       Date:  2014-05-30       Impact factor: 1.568

10.  The Level of Europium-154 Contaminating Samarium-153-EDTMP Activates the Radiation Alarm System at the US Homeland Security Checkpoints.

Authors:  Mohammed Najeeb Al Hallak; Matt McCurdy; Nicolas Zouain; Justin Hayes
Journal:  Case Rep Oncol       Date:  2009-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.